Home
    • Plans Blog Contact
    Vir Biotechnology Inc logo

    Vir Biotechnology Inc

    VIR
    Last price US$8.69
    Market cap US$1.4b
    12M price change 50.63%
    Loading the 12-month Mave Thesis and 1-month news signal

    Industry and sector peers, plus broader research alternatives

    Browse companies
    Halozyme Therapeutics IncHALO Industry peer Corcept Therapeutics IncorporatedCORT Industry peer Exelixis IncEXEL Industry peer Zoetis IncZTS Sector peer
    Overview Earnings Report Price History News Financial Statements
    Dashboard Funda..tals Prediction Screener Map

    Vir Biotechnology Inc Overview

    Industry: Biotechnology

    Sector: Healthcare

    Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. The company was incorporated in 2016 and is headquartered in San Francisco, California. Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for Read More

    Reported Results

    What the company reported, with filing details kept small.

    Filed May 06, 2026

    Quarterly result summary

    Revenue was -$0M (-41% YoY). Net loss was -$125.7M. Cash was $809.3M.

    Revenue -$0M -41% YoY
    Net loss -$125.7M reported
    Cash $809.3M reported

    What changed

    • Revenue -41% YoY to -$0M.

    Guidance / outlook

    The Company anticipates initiating pivotal Phase 3 trials in 2027. 1 • Positive updated Phase 1 data for VIR-5500 monotherapy showed dose-dependent anti-tumor activity and a well-tolerated safety profile in patients with mCRPC.

    Earnings release Open filing

    Source: SEC EDGAR company-filed earnings materials. Dates are shown only for verification; review the source filing before relying on extracted report details.

    Other recent earnings materials
    SEC filing 10-Q May 07, 2026 SEC filing 8-K May 06, 2026 Earnings release ASTELLAS AND VIR BIO JOINT PRESS RELEASE Feb 23, 2026 SEC filing 10-K Feb 23, 2026 Earnings release EARNINGS RELEASE Feb 23, 2026 Earnings material VIR-5500 DATA PRESS RELEASE Feb 23, 2026 SEC filing 8-K Jan 12, 2026 SEC filing 10-Q Nov 05, 2025 Earnings release Earnings release Nov 05, 2025 SEC filing 8-K Nov 05, 2025 SEC filing 10-Q Aug 06, 2025

    Prediction-grade evidence

    Recent News

    Company-relevant articles from sources that pass the Mave Signal relevance and reliability checks.

    Financial Statements

    Company-reported SEC EDGAR facts organized into the three core statements.

    Verified SEC statements load when this section enters view.

    Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.

    Vir Biotechnology Inc logo

    Vir Biotechnology Inc

    US$8.69

    US$1.4b

    -7.85%

    50.63%